Table. Bactericidal antibody titers in pooled serum samples from infants vaccinated with Bexsero and adolescents immunized with Menveo against 6 invasive clinical Neisseria meningitidis serogroup W isolates in England and Wales, UK, during 2011–2012*.

Isolate	Adolescents receiving Menveo			Infants receiving Bexsero
	Positive control†			Negative control‡	Pool 1§	Pool 2¶	Pool 3#	Pool 4**
	Before	After
M11–240417	<16	256		<2	64	128	>128	>128
M11–240427	<16	128		<2	32	32	64	64
M11–240802	<16	512		<2	32	>64	>64	>64
M12–240016	<16	256		<2	32	32	64	128
M11–240798	<16	512		<2	>64	>64	>64	>64
M12–240754	<16	256		<2	64	64	>64	>64

*Human serum bactericidal antibody titers against 6 meningococcal group W clinical isolates belonging to ST-11 clonal complex using pooled serum from adolescents immunized with the MenACWY conjugate vaccine, Menveo, and from infants immunized with the protein-based, multicomponent meningococcal vaccine, Bexsero.
†Pooled serum samples from adolescents 11–17 years of age before and 1 month after receiving a single dose of MenACWY (Menveo) conjugate vaccine (n = 10).
‡Pooled prevaccination serum samples from infants at 2 months of age (n = 180) (control).
§Pooled serum samples from infants who received 3 doses of vaccine at 2, 3, and 4 months of age and had a blood sample taken 1 month after the last dose of vaccine (n = 56).
¶Pooled serum samples from infants who received 3 doses of vaccine at 2, 4, and 6 months of age and had a blood sample taken 1 month after the last dose of vaccine (n = 47).
#Pooled serum samples from infants who received 3 doses of vaccine at 2, 4, and 6 months of age plus a booster at 12 months and had a blood sample taken 1 month after the booster (n = 72).
**Pooled serum samples from an additional cohort of infants who also received 3 doses of vaccine at 2, 4, and 6 months of age plus a booster at 12 months and had a blood sample taken 1 month after the booster (n = 94).